88 / 89
88
bevacizumab and bortezomib versus bortezomib in
relapsed or refractory multiple myeloma. Cancer
2013;119:339-47.
76.
Richardson PG, Sonneveld P, Schuster MW, Irwin D,
Stadtmauer EA, Facon T, et al. Bortezomib or high-dose
dexamethasone for relapsed multiple myeloma. N Engl J
Med 2005;352:2487-98. Comment in: N Engl J Med
2005;352:2546-8.
77.
Richardson PG, Sonneveld P, Schuster MW, Irwin D,
Stadtmauer EA, Facon T, et al. Safety and efficacy of
bortezomib in high-risk and elderly patients with
relapsed multiple myeloma. Br J Haematol 2007;137:429-
35.
78.
Richardson PG, Sonneveld P, Schuster M, Irwin D,
Stadtmauer E, Facon T, et al. Extended follow-up of a
phase 3 trial in relapsed multiple myeloma: final time-to-
event results of the APEX trial. Blood 2007;110:3557-60.
79.
Lee SJ, Richardson PG, Sonneveld P, Schuster MW, Irwin
D, San Miguel JF, et al. Bortezomib is associated with
better health-related quality of life than high-dose
dexamethasone in patients with relapsed multiple
myeloma: results from the APEX study. Br J Haematol
2008;143:511-9.
80.
McCloskey EV, MacLennan IC, Drayson MT, Chapman C,
Dunn J, Kanis JA. A randomized trial of the effect of
clodronate on skeletal morbidity in multiple myeloma.
MRC Working Party on Leukaemia in Adults. Br J
Haematol 1998;100:317-25.
81.
Menssen HD, Sakalová A, Fontana A, Herrmann Z,
Boewer C, Facon T, et al. Effects of long-term intravenous
ibandronate therapy on skeletal-related events, survival,
and bone resorption markers in patients with advanced
multiple myeloma. J Clin Oncol 2002;20:2353-9.